Selectively purify nonfucosylated antibodies
Zepteon has developed a breakthrough antibody development and manufacturing technology that enables biopharmaceutical companies to evaluate and tune their drug potency. This is accomplished by separating high potency antibodies (nonfucosylated) from complex mixtures ...
Next Gen Antibody Platform
Boreal is developing a new antibody discovery technology that involves breaking tolerance in vivo to generate broader antibody diversity against tough to immunize drug targets, like GPCRs and other transmembrane proteins.
Put your invite codes to work
InvitationCode is a free tool for maximizing your rewards from referrals, whether you’re a blogger, an early-adopter or just an helpful friend. Download a list of apps that pay generous comissions.
Oncolinx is developing next-generation, targeted cancer therapeutics.
Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment. These therapies can be targeted to nearly ...